Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [912]

Onset and treatment of infantile leukaemia

Dr Anindita Roy - University of Oxford, Oxford, UK

Onset and treatment of infantile leukaemia ( Dr Anindita Roy - University of Oxford, Oxford, UK )

Editor’s Choice for May 2018

Prof Gordon McVie - Founding Editor, ecancer

Editor’s Choice for May 2018 ( Prof Gordon McVie - Founding Editor, ecancer )

Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer

Dr Arjun Balar - NYU Langone Medical Center, New York, USA

Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer ( Dr Arjun Balar - NYU Langone Medical Center, New York, USA )

Phase I taselisib results and a cell-free DNA assay

Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA

Phase I taselisib results and a cell-free DNA assay ( Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA )

Safety indications in mouse models treated with full doses of MEK inhibitors...

Dr Carmine Fedele - Laura and Isaac Perlmutter Cancer Center at New York...

Safety indications in mouse models treated with full doses of MEK inhibitors and SHP099 ( Dr Carmine Fedele - Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical, New York, USA )

A variety of approaches to measure the efficacy of PARP inhibitors

Dr Elisabetta Leo - AstraZeneca, Cambridge, UK

A variety of approaches to measure the efficacy of PARP inhibitors ( Dr Elisabetta Leo - AstraZeneca, Cambridge, UK )

Development and clinical indications of PARP inhibitors

Dr Mark O'Connor - AstraZeneca, Cambridge, UK

Development and clinical indications of PARP inhibitors ( Dr Mark O'Connor - AstraZeneca, Cambridge, UK )

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL

Dr Susan Galbraith - AstraZeneca, Cambridge, UK

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL ( Dr Susan Galbraith - AstraZeneca, Cambridge, UK )

Clinical development and economic prospects of CAR T cell immunotherapies

Dr Bob Velamehr - Fate Therapeutics, La Jolla, USA

Clinical development and economic prospects of CAR T cell immunotherapies ( Dr Bob Velamehr - Fate Therapeutics, La Jolla, USA )

The best sequence of anti-HER2 therapy in metastatic breast cancer

Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain

The best sequence of anti-HER2 therapy in metastatic breast cancer ( Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain )

ESO-ESMO-ABC guidelines in metastatic breast cancer

Dr Nagi El Saghir - American University of Beirut, Beirut, Lebanon

ESO-ESMO-ABC guidelines in metastatic breast cancer ( Dr Nagi El Saghir - American University of Beirut, Beirut, Lebanon )

ESMO 2017 roundup with Dr Bishal Gyawali (2/2)

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan

ESMO 2017 roundup with Dr Bishal Gyawali (2/2) ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )

More from ecancer